ZVRA vs. XERS
ZVRA (Zevra Therapeutics Inc.) and XERS (Xeris Biopharma Holdings, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, ZVRA returned -1.18%/yr vs 21.35%/yr for XERS. Their 0.24 correlation means their historical movements had little consistent relationship.
Performance
ZVRA vs. XERS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ZVRA achieves a 6.14% return, which is significantly higher than XERS's 2.93% return.
ZVRA
- 1D
- -1.35%
- 1M
- -31.14%
- 6M
- 5.67%
- YTD
- 6.14%
- 1Y
- -14.40%
- 3Y*
- 24.74%
- 5Y*
- -1.18%
- 10Y*
- -17.62%
- ALL TIME*
- -23.23%
XERS
- 1D
- -4.04%
- 1M
- 1.00%
- 6M
- 9.78%
- YTD
- 2.93%
- 1Y
- 58.74%
- 3Y*
- 44.28%
- 5Y*
- 21.35%
- 10Y*
- —
- ALL TIME*
- -7.90%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $11.42M | $15.11M | $13.85M | |
| $18.33M | $18.68M | $21.76M |
ZVRA vs. XERS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
ZVRA Zevra Therapeutics Inc. | 6.14% | 7.43% | 27.33% | 42.70% | -47.30% | -22.23% | 84.70% | -78.71% | -72.62% |
XERS Xeris Biopharma Holdings, Inc. | 2.93% | 131.56% | 44.26% | 76.69% | -54.61% | -40.45% | -30.21% | -58.53% | 7.94% |
Correlation
The correlation between ZVRA and XERS is 0.40, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.40 |
Correlation (3Y) Balances recent behavior with more history. | 0.36 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.33 |
Correlation (All Time) Calculated using the full available price history since Jun 21, 2018 | 0.24 |
The correlation between ZVRA and XERS shifts across timeframes, from 0.24 (all time) to 0.40 (1 year), reflecting how their relationship changes across market environments.
Fundamentals
ZVRA:
$562.18M
XERS:
$1.39B
ZVRA:
$2.15
XERS:
$0.07
ZVRA:
4.43
XERS:
120.07
ZVRA:
4.50
XERS:
4.58
ZVRA:
2.78
XERS:
110.31
ZVRA:
$122.29M
XERS:
$314.85M
ZVRA:
$104.94M
XERS:
$187.04M
ZVRA:
$149.15M
XERS:
$41.72M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ZVRA vs. XERS — Risk / Return Rank
ZVRA
XERS
ZVRA vs. XERS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Zevra Therapeutics Inc. (ZVRA) and Xeris Biopharma Holdings, Inc. (XERS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ZVRA | XERS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.29 | ||
| Sortino ratioReturn per unit of downside risk | -1.57 | ||
| Omega ratioGain probability vs. loss probability | 1.02 | 1.23 | -0.22 |
| Calmar ratioReturn relative to maximum drawdown | -0.36 | 1.27 | -1.63 |
| Martin ratioReturn relative to average drawdown | -0.65 | 2.17 | -2.82 |
Loading charts...
Drawdowns
ZVRA vs. XERS - Drawdown Comparison
The maximum ZVRA drawdown since its inception was -99.27%, roughly equal to the maximum XERS drawdown of -96.22%. Use the drawdown chart below to compare losses from any high point for ZVRA and XERS.
Loading charts...
Drawdown Indicators
| ZVRA | XERS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.27% | -96.22% | -3.05% |
Max Drawdown (1Y)Largest decline over 1 year | -40.40% | -46.57% | +6.17% |
Max Drawdown (3Y)Largest decline over 3 years | -43.47% | -47.20% | +3.73% |
Max Drawdown (5Y)Largest decline over 5 years | -60.97% | -66.34% | +5.37% |
Max Drawdown (10Y)Largest decline over 10 years | -97.85% | — | — |
Current DrawdownCurrent decline from peak | -97.48% | -70.33% | -27.15% |
Average DrawdownAverage peak-to-trough decline | -86.53% | -78.86% | -7.67% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 22.22% | 27.13% | -4.91% |
Volatility
ZVRA vs. XERS - Volatility Comparison
Zevra Therapeutics Inc. (ZVRA) has a higher volatility of 29.44% compared to Xeris Biopharma Holdings, Inc. (XERS) at 13.14%. This indicates that ZVRA's price experiences larger fluctuations and is considered to be riskier than XERS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ZVRA | XERS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 29.44% | 13.14% | +16.30% |
Volatility (6M)Calculated over the trailing 6-month period | 49.17% | 30.94% | +18.23% |
Volatility (1Y)Calculated over the trailing 1-year period | 65.35% | 55.25% | +10.10% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 61.11% | 67.85% | -6.74% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 81.05% | 79.23% | +1.82% |
Dividends
ZVRA vs. XERS - Dividend Comparison
Neither ZVRA nor XERS has paid dividends to shareholders.
Financials
ZVRA vs. XERS - Financials Comparison
This section allows you to compare key financial metrics between Zevra Therapeutics Inc. and Xeris Biopharma Holdings, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
ZVRA and XERS have a correlation of 0.40, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ZVRA has higher volatility (29.44%) compared to XERS (13.14%). In terms of maximum drawdown, ZVRA dropped -99.27% vs XERS's -96.22%.
XERS currently has the higher Sharpe Ratio (1.07 vs -0.22), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ZVRA and XERS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer